Kim et al [32] collected serial plasma samples of two CRC cancer patients during treatment of cetuximab and observed newly-emerged KRAS mutations in ctDNA results 1.5 months before radiologic progression. This evidence concerns the gene KRAS and colorectal carcinoma.